Hologic Inc (FRA:HO1)
€ 69.5 0.5 (0.72%) Market Cap: 16.16 Bil Enterprise Value: 16.51 Bil PE Ratio: 38.19 PB Ratio: 3.63 GF Score: 85/100

Hologic Inc at Raymond James Institutional Investors Conference (Virtual) Transcript

Mar 01, 2021 / 06:20PM GMT
Release Date Price: €60 (+0.84%)
Jayson Tyler Bedford
Raymond James & Associates, Inc., Research Division - Senior Medical Supplies and Devices Analyst

Okay. I think we can get started here. My name is Jayson Bedford, Medical Device Analyst here at Raymond James. Welcome to the afternoon session, at least on the East Coast, to the Raymond James -- 42nd Annual Raymond James Institutional Investor Conference. Very pleased to have with us today Hologic. Representing Hologic, we've got Mike Watts, VP of Investor Relations and Corporate Communications; and Francis Pruell, Director of Investor Relations. So there'll be no presentation. It will be straight fireside.

Just wanted to, before we begin, kind of, at least frame the investment dynamic as we see it at least. You've got a little less than half of your revenue stemming from COVID testing, a little over half currently from non-COVID testing. There's clearly a debate out there on the durability and relative share of the testing market, but pretty much everyone agrees testing will come down over time. We've started to see that in the public data. Like, this is factored into

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot